Pivotal phase III study of T cell vaccine Tcelna in patients with relapsing-remitting multiple sclerosis.
Phase of Trial: Phase III
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Imilecleucel-T (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Acer Therapeutics; Opexa Therapeutics
- 19 Sep 2017 According to a Acer Therapeutics media release, Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics.
- 08 Nov 2011 Opexa plans to initiate a phase IIb trial in patients with secondary progressive multiple sclerosis, while remaining committed to further advancing the product in relapsing-remitting multiple sclerosis at a later date.
- 06 Jan 2011 New trial record